More on GILD
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $127.57 |
|
|||
| Open | $127.59 | ||||
| 52 Wk High | $108.63 | ||||
| 52 Wk Low | $71.39 | ||||
| Day High | $129.86 | ||||
| Day Low | $127.50 | ||||
| P/E | 71.27 | ||||
| EPS | $1.81 | ||||
| Volume | 6,235,856 | ||||
- Form 4 GILEAD SCIENCES, INC. For: Jun 01 Filed by: O'Day Daniel Patrick
- GILD reports positive results for Livdelzi in PBC patients with mild ALP elevation
- Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
- Form 144 GILEAD SCIENCES, INC. Filed by: O'Day Daniel Patrick
- RBC Capital Reiterates Sector Perform Rating on Gilead Sciences (GILD)
- Gilead's Livdelzi shows sustained liver marker improvement in PBC study
- Phase 3 ASSURE Interim Data: Majority of People in the Study with ALP 1–1.67×ULN Achieved High and Sustained Composite ALP Normalization at 24 Months with Gilead’s Livdelzi (Seladelpar)
- FDA approves Gilead's Hepcludex as first HDV treatment in U.S.
- FDA Grants Accelerated Approval to Gilead’s Hepcludex® (bulevirtide-gmod), the First and Only Approved Treatment for Chronic Hepatitis Delta Virus (HDV)
- FDA Approves Hepcludex injection to treat chronic Hepatitis Delta virus infection in adults w/o Cirrhosis or w/ compensated Cirrhosis
Entities mentioned with GILD
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Options | View Related Stories »
- Show More...
